

ENGAGE

An Alzheimer's Research Study

Aim

To evaluate the efficacy of the human recombinant anti-amyloid beta monoclonal antibody, Aducanumab, in slowing cognitive and functional impairment in subjects with early symptomatic Alzheimer's disease (AD)

Phase III

A two-year multicenter, international, randomized, double-blind, placebo-controlled, parallel-group study

Hypothesis

Aducanumab penetrates into the brain and clears existing plaques of AD patients by binding to aggregated forms of beta amyloid, including soluble oligomers and insoluble fibrils; and initiates a microglial-mediated phagocytosis and clearance of β -amyloid through the IgG1 backbone.

At the end of the double-blind treatment period, subjects who meet entry criteria may enter an optional two-year long-term, safety and efficacy extension period in which all subjects will receive Aducanumab.

Trial NCT02484547

Funding

- Biogen
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the ENGAGE Study participants must:

- be between 50-85 years and generally healthy,
- have an MMSE score of 24-30, and
- have a reliable carer who can assist him or her during the study.

Status

Currently enrolling.

Ethics approval

Bellberry Human Research Ethics Committee
(2015-06-390)

Principal Investigator

Professor Peter K Panegyres, MD PhD FRACP
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005

Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au